RECURSION PHARMACEUTICALS, INC. (RXRX) · INSIDERData sourcesSEC Form 44h ago
House PTR4h ago
SEC 13F4h ago
Robinhood Chain4h ago
Public companyRECURSION PHARMACEUTICALS, INC.
RXRXCIK 0001601830
Price$3.52
1 year-29.0%
Disclosed transactions49
Buys / sells0 / 18
Max Insider Score24
Connections with evidence8
RXRX · disclosed activity on price
| Score | Actor | Security | Side | Value | Executed | Disclosed | Lag | Source | Evidence |
|---|
| 4 | | RXRXRECURSION PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $155K 40.0K sh | Nov 3, 2026 | Nov 4, 2026 |
| 9 | | RXRXRECURSION PHARMACEUTICALS, INC. Grant or award | A | — 156.7K sh | Nov 2, 2026 | Nov 4, 2026 traded Nov 2, 2026 | +2d | SEC Form 4 | |
| 12 | HDHallett DavidChief Scientific Officer | RXRXRECURSION PHARMACEUTICALS, INC. Tax withholding | F | $84K 26.7K sh | Aug 17, 2026 | Aug 18, 2026 traded Aug 17, 2026 | +1d | SEC Form 4 | |
| 11 | KNKhan NajatDirector, CEO and President | RXRXRECURSION PHARMACEUTICALS, INC. Tax withholding | F | $254K 80.5K sh | Aug 17, 2026 | Aug 18, 2026 traded Aug 17, 2026 | +1d | SEC Form 4 | |
| 23 | KNKhan NajatDirector, CEO and President | RXRXRECURSION PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $84K 23.6K sh | Jun 5, 2026 | Jun 5, 2026 traded Jun 5, 2026 | +0d | SEC Form 4 | |
| 0 | GCGibson ChristopherDirector | RXRXRECURSION PHARMACEUTICALS, INC. Derivative conversion · 10b5-1 plan | C | — 40.0K sh | Jun 5, 2026 | Jun 5, 2026 traded Jun 5, 2026 | +0d | SEC Form 4 | |
| 0 | GCGibson ChristopherDirector | RXRXRECURSION PHARMACEUTICALS, INC. Derivative conversion · 10b5-1 plan | C | — 40.0K sh | Jun 5, 2026 | Jun 5, 2026 traded Jun 5, 2026 | +0d | SEC Form 4 | |
| 16 | GCGibson ChristopherDirector | RXRXRECURSION PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $145K 40.0K sh | Jun 5, 2026 | Jun 5, 2026 traded Jun 5, 2026 | +0d | SEC Form 4 | |
| 19 | | RXRXRECURSION PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $110K 30.0K sh | Jun 2, 2026 | Jun 4, 2026 traded Jun 2, 2026 | +2d | SEC Form 4 | |
| 24 | BNBumpus NamandjeDirector | RXRXRECURSION PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $16K 4,386 sh | Jun 3, 2026 | Jun 4, 2026 traded Jun 3, 2026 | +1d | SEC Form 4 | |
| 12 | KNKhan NajatDirector, CEO and President | RXRXRECURSION PHARMACEUTICALS, INC. Tax withholding | F | $191K 62.7K sh | May 15, 2026 | May 19, 2026 traded May 15, 2026 | +4d | SEC Form 4 | |
| 12 | HDHallett DavidChief Scientific Officer | RXRXRECURSION PHARMACEUTICALS, INC. Tax withholding | F | $81K 26.7K sh | May 15, 2026 | May 19, 2026 traded May 15, 2026 | +4d | SEC Form 4 | |
| 9 | | RXRXRECURSION PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $106K 30.0K sh | May 5, 2026 | May 7, 2026 traded May 5, 2026 | +2d | SEC Form 4 | |
| 0 | GCGibson ChristopherDirector | RXRXRECURSION PHARMACEUTICALS, INC. Derivative conversion · 10b5-1 plan | C | — 40.0K sh | Apr 22, 2026 | Apr 24, 2026 traded Apr 22, 2026 | +2d | SEC Form 4 | |
| 0 | GCGibson ChristopherDirector | RXRXRECURSION PHARMACEUTICALS, INC. Derivative conversion · 10b5-1 plan | C | — 40.0K sh | Apr 22, 2026 | Apr 24, 2026 traded Apr 22, 2026 | +2d | SEC Form 4 | |
| 6 | GCGibson ChristopherDirector | RXRXRECURSION PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $144K 40.0K sh | Apr 22, 2026 | Apr 24, 2026 traded Apr 22, 2026 | +2d | SEC Form 4 | |
| 8 | TRTaylor Ben RChief Financial Officer | RXRXRECURSION PHARMACEUTICALS, INC. Tax withholding | F | $149K 48.0K sh | Apr 6, 2026 | Apr 8, 2026 traded Apr 6, 2026 | +2d | SEC Form 4 | |
| 6 | GCGibson ChristopherDirector | RXRXRECURSION PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $124K 40.0K sh | Apr 7, 2026 | Apr 8, 2026 traded Apr 7, 2026 | +1d | SEC Form 4 | |
| 0 | GCGibson ChristopherDirector | RXRXRECURSION PHARMACEUTICALS, INC. Derivative conversion · 10b5-1 plan | C | — 40.0K sh | Apr 7, 2026 | Apr 8, 2026 traded Apr 7, 2026 | +1d | SEC Form 4 | |
| 0 | GCGibson ChristopherDirector | RXRXRECURSION PHARMACEUTICALS, INC. Derivative conversion · 10b5-1 plan | C | — 40.0K sh | Apr 7, 2026 | Apr 8, 2026 traded Apr 7, 2026 | +1d | SEC Form 4 | |
| 9 | | RXRXRECURSION PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $93K 30.0K sh | Apr 7, 2026 | Apr 8, 2026 traded Apr 7, 2026 | +1d | SEC Form 4 | |
| 0 | GCGibson ChristopherDirector | RXRXRECURSION PHARMACEUTICALS, INC. Derivative conversion · 10b5-1 plan | C | — 40.0K sh | Jan 20, 2026 | Jan 22, 2026 traded Jan 20, 2026 | +2d | SEC Form 4 | |
| 0 | GCGibson ChristopherDirector | RXRXRECURSION PHARMACEUTICALS, INC. Derivative conversion · 10b5-1 plan | C | — 40.0K sh | Jan 20, 2026 | Jan 22, 2026 traded Jan 20, 2026 | +2d | SEC Form 4 | |
| 9 | GCGibson ChristopherDirector | RXRXRECURSION PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $179K 40.0K sh | Jan 20, 2026 | Jan 22, 2026 traded Jan 20, 2026 | +2d | SEC Form 4 | |
| 17 | | RXRXRECURSION PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $959K 220.0K sh | Jan 6, 2026 | Jan 8, 2026 traded Jan 6, 2026 | +2d | SEC Form 4 | |
| 0 | GCGibson ChristopherDirector | RXRXRECURSION PHARMACEUTICALS, INC. Derivative conversion · 10b5-1 plan | C | — 60.0K sh | Jan 5, 2026 | Jan 7, 2026 traded Jan 5, 2026 | +2d | SEC Form 4 | |
| 0 | GCGibson ChristopherDirector | RXRXRECURSION PHARMACEUTICALS, INC. Derivative conversion · 10b5-1 plan | C | — 60.0K sh | Jan 5, 2026 | Jan 7, 2026 traded Jan 5, 2026 | +2d | SEC Form 4 | |
| 0 | GCGibson ChristopherDirector | RXRXRECURSION PHARMACEUTICALS, INC. Gift · 10b5-1 plan | G | — 20.0K sh | Jan 5, 2026 | Jan 7, 2026 traded Jan 5, 2026 | +2d | SEC Form 4 | |
| 14 | GCGibson ChristopherDirector | RXRXRECURSION PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $170K 40.0K sh | Jan 5, 2026 | Jan 7, 2026 traded Jan 5, 2026 | +2d | SEC Form 4 | |
| 18 | TRTaylor Ben RChief Financial Officer | RXRXRECURSION PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $89K 21.4K sh | Dec 29, 2025 | Dec 30, 2025 traded Dec 29, 2025 | +1d | SEC Form 4 | |
| 9 | GCGibson ChristopherDirector, Chief Executive Officer | RXRXRECURSION PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $180K 40.0K sh | Dec 19, 2025 | Dec 19, 2025 traded Dec 19, 2025 | +0d | SEC Form 4 | |
| 0 | GCGibson ChristopherDirector, Chief Executive Officer | RXRXRECURSION PHARMACEUTICALS, INC. Derivative conversion · 10b5-1 plan | C | — 40.0K sh | Dec 19, 2025 | Dec 19, 2025 traded Dec 19, 2025 | +0d | SEC Form 4 | |
| 0 | GCGibson ChristopherDirector, Chief Executive Officer | RXRXRECURSION PHARMACEUTICALS, INC. Derivative conversion · 10b5-1 plan | C | — 40.0K sh | Dec 19, 2025 | Dec 19, 2025 traded Dec 19, 2025 | +0d | SEC Form 4 | |
| 0 | GCGibson ChristopherDirector, Chief Executive Officer | RXRXRECURSION PHARMACEUTICALS, INC. Derivative conversion · 10b5-1 plan | C | — 60.0K sh | Dec 4, 2025 | Dec 5, 2025 traded Dec 4, 2025 | +1d | SEC Form 4 | |
| 0 | GCGibson ChristopherDirector, Chief Executive Officer | RXRXRECURSION PHARMACEUTICALS, INC. Gift · 10b5-1 plan | G | — 20.0K sh | Dec 4, 2025 | Dec 5, 2025 traded Dec 4, 2025 | +1d | SEC Form 4 | |
| 0 | GCGibson ChristopherDirector, Chief Executive Officer | RXRXRECURSION PHARMACEUTICALS, INC. Derivative conversion · 10b5-1 plan | C | — 60.0K sh | Dec 4, 2025 | Dec 5, 2025 traded Dec 4, 2025 | +1d | SEC Form 4 | |
| 9 | GCGibson ChristopherDirector, Chief Executive Officer | RXRXRECURSION PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $185K 40.0K sh | Dec 4, 2025 | Dec 5, 2025 traded Dec 4, 2025 | +1d | SEC Form 4 | |
| 16 | | RXRXRECURSION PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $961K 220.0K sh | Dec 2, 2025 | Dec 4, 2025 traded Dec 2, 2025 | +2d | SEC Form 4 | |
| 0 | GCGibson ChristopherDirector, Chief Executive Officer | RXRXRECURSION PHARMACEUTICALS, INC. Tax withholding · 10b5-1 plan | F | $167K 40.4K sh | Nov 17, 2025 | Nov 19, 2025 traded Nov 17, 2025 | +2d | SEC Form 4 | |
| 12 | KNKhan NajatDirector, Chief R&D Commercial Officer | RXRXRECURSION PHARMACEUTICALS, INC. Tax withholding | F | $73K 17.6K sh | Nov 17, 2025 | Nov 19, 2025 traded Nov 17, 2025 | +2d | SEC Form 4 | |
| 0 | GCGibson ChristopherDirector, Chief Executive Officer | RXRXRECURSION PHARMACEUTICALS, INC. Derivative conversion · 10b5-1 plan | C | — 40.0K sh | Nov 19, 2025 | Nov 19, 2025 traded Nov 19, 2025 | +0d | SEC Form 4 | |
| 9 | GCGibson ChristopherDirector, Chief Executive Officer | RXRXRECURSION PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $166K 40.0K sh | Nov 19, 2025 | Nov 19, 2025 traded Nov 19, 2025 | +0d | SEC Form 4 | |
| 0 | GCGibson ChristopherDirector, Chief Executive Officer | RXRXRECURSION PHARMACEUTICALS, INC. Derivative conversion · 10b5-1 plan | C | — 40.0K sh | Nov 19, 2025 | Nov 19, 2025 traded Nov 19, 2025 | +0d | SEC Form 4 | |
| 8 | GCGibson ChristopherDirector, Chief Executive Officer | RXRXRECURSION PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $208K 40.0K sh | Nov 4, 2025 | Nov 6, 2025 traded Nov 4, 2025 | +2d | SEC Form 4 | |
| 13 | KNKhan NajatDirector, Chief R&D Commercial Officer | RXRXRECURSION PHARMACEUTICALS, INC. Grant or award | A | — 84.9K sh | Nov 5, 2025 | Nov 6, 2025 traded Nov 5, 2025 | +1d | SEC Form 4 | |
| 3 | GCGibson ChristopherDirector, Chief Executive Officer | RXRXRECURSION PHARMACEUTICALS, INC. Derivative conversion · 10b5-1 plan | C | — 60.0K sh | Nov 4, 2025 | Nov 6, 2025 traded Nov 4, 2025 | +2d | SEC Form 4 | |
| 0 | GCGibson ChristopherDirector, Chief Executive Officer | RXRXRECURSION PHARMACEUTICALS, INC. Derivative conversion · 10b5-1 plan | C | — 60.0K sh | Nov 4, 2025 | Nov 6, 2025 traded Nov 4, 2025 | +2d | SEC Form 4 | |
| 2 | GCGibson ChristopherDirector, Chief Executive Officer | RXRXRECURSION PHARMACEUTICALS, INC. Gift · 10b5-1 plan | G | — 20.0K sh | Nov 4, 2025 | Nov 6, 2025 traded Nov 4, 2025 | +2d | SEC Form 4 | |
| 9 | KNKhan NajatDirector, Chief R&D Commercial Officer | RXRXRECURSION PHARMACEUTICALS, INC. Grant or award | A | — 169.9K sh | Nov 5, 2025 | Nov 6, 2025 traded Nov 5, 2025 | +1d | SEC Form 4 | |
Chief Financial Officer · Dec 30, 2025
Khan NajatDirector, Chief R&D Commercial Officer · Nov 6, 2025 Planned sales and 5% stakes
Form 144, 13D and 13G